DEAR FRIENDS OF TAG,

It is a privilege to work with some of the world’s smartest, most dedicated, and highly accomplished AIDS activists. It is equally a privilege to be working with an amazing and committed board of directors and with TAG’s incredible family and friends. I’m writing to share with you our accomplishments in 2007. You made them happen. And I am writing to urge you to continue and expand your support for the Treatment Action Group in 2008 and beyond.

In December 2007 at our annual Research in Action Award (RIAA) ceremony, Harvard University researcher and RIAA recipient Dr. Jim Yong Kim made some remarks about TAG’s work that I wanted to share with you. “AIDS activism has changed our society indelibly. Activists have awakened the entire world to the suffering of people living with HIV and fundamentally altered the way we view science, drug development, and even sexuality.”

I couldn’t have said it better myself. Given the urgency of the AIDS epidemic and the unmet needs and demands AIDS research is facing while many people with HIV still need lifelong services, better treatment, and, ultimately, a cure, I am asking you to step up your support for the Treatment Action Group and its important work. Thanks for all you’ve given, and for giving more.

Barbara Hughes
President, Board of Directors

WHAT’S INSIDE

• TAG at a Glance 2007
• TAG Programs
• TAG Limited Edition 2007
• 2007 Contributors
• The Palm Donor Circle
• 2007 Financials

Research in Action Awards 2007

Treatment Action Group’s 2007 Research in Action Awards (RIAA) honored public health leader Dr. Jim Yong Kim, New York City Council Speaker Christine C. Quinn, and gay rights activist David Mixner.

TAG’s 2007 Research in Action Awards, held at the Drawing Center in New York City on December 9, 2007, honored three individuals who have made significant contributions to AIDS research and activism. “We are honoring three tireless workers who fight AIDS through public health, public service, and social activism,” said Mark Harrington, executive director of TAG.

Dr. Jim Yong Kim
Jim Yong Kim, MD, PhD, is the Director of the Francois-Xavier Bagnoud Center for Health and Human Rights at the Harvard School of Public Health, as well as a professor at Harvard Medical School and Chair of the Harvard Medical School Department of Social Medicine. The focus of the Center under Dr. Kim’s leadership is HIV/AIDS—especially...
efforts to achieve universal access to HIV prevention, treatment, and care. He is the former director of the World Health Organization’s HIV/AIDS Department. Dr. Kim is the recipient of a 2003 MacArthur “Genius” Award, and in 2006 was selected as one of Time magazine’s 100 most influential people.

The Honorable Christine C. Quinn
As the first woman, openly gay, and Irish Speaker of the New York City Council, Christine Quinn brings a new perspective to the diverse challenges facing each of New York City’s distinct communities. One of the fiercest advocates for the creation, preservation, and improvement of New York City’s HIV/AIDS Services Administration, Speaker Quinn has been a longtime pioneer for equal rights and comprehensive health care. She has been rated one of the 50 most powerful women in New York City by the New York Post, and one of the most influential New Yorkers by New York Magazine.

David Mixner
Once named by Newsweek as the most powerful gay man in America, David Mixner has been a highly regarded leader in American politics and international human rights for over 40 years. Mr. Mixner is an author of books and screenplays, as well as having written for various influential publications. David Mixner has for decades been an unofficial advisor to elected officials and business leaders on domestic and foreign policy.

The benefit was hosted by commodienc Jackie Hoffman. Artist Carrie Yamaoka donated a limited-edition series of artworks that were displayed during the evening. The event raised over $100,000 to support TAG’s work.

2007 AT A GLANCE

JANUARY
January 2007: TAG starts the first year of its four-year TB/AIDS Advocacy Project, supported by the Bill & Melinda Gates Foundation. TAG makes a presentation at a New York workshop on TB research and development sponsored by Médecins sans Frontières (MSF).

FEBRUARY
TAG staff participate in the annual Retrovirus Conference in Los Angeles. TAG hires its new TB/AIDS coordinator Claire Wingfield, MPH, an experienced AIDS advocate with previous experience at the National AIDS Treatment Advocacy Project and the Asian Pacific Islander Wellness Center. TAG’s Executive Director Mark Harrington is profiled in Nature Medicine (Nature Medicine 13, 270) and gives a talk on TB research funding needs at the North American TB Union meeting in Vancouver, B.C.

MARCH
TAG’s Mark Harrington, TB/AIDS Project Director Javid Syed, and Claire Wingfield visit tuberculosis and HIV research sites and community activist organizations in Uganda and South Africa. TAG’s HCV/HIV Project Director Tracy Swan organizes and speaks at the international workshop on research and access to experimental drugs for hepatitis C virus (HCV) for HCV/HIV coinfected persons in Sitges, Spain; this results in a manifesto for coinfection trials known as the Sitges Statement. Mark Harrington and Javid Syed attend the Keystone TB Pathogenesis Symposium in Vancouver, B.C.

APRIL

MAY
Mark Harrington testifies on the need for expanded research to combat multi- and extensively drug-resistant (M/XDR) tuberculosis at the National Institute of Allergy and Infectious Disease Advisory Council meeting. TAG sponsors a workshop on research activism in Rio de Janeiro, Brazil, and sponsors the first community advocacy group meeting of the Centers for Disease Control and Prevention (CDC)-funded Tuberculosis Trials Consortium (TBTC).

JUNE
Britain’s prestigious medical journal The Lancet publishes an article cowritten by Mark Harrington on the need for expanded efforts to detect smear-negative and extrapulmonary TB among people with HIV [Lancet; 369:2042–2049]. TAG organizes an activist workshop in Cape Town, South Africa and sponsors a meeting of global TB/HIV activists with the World Health Organization’s Stop TB Department, the Stop TB Partnership, and the Foundation for Innovative New Diagnostics in Geneva, Switzerland. TAG forms a partnership with the International Community of Women Living with HIV/East Africa (ICW/East Africa) to collaborate on TB/HIV activism.

1. Research in Action Award recipient Dr. Jim Yong Kim discusses health policy with TAG TB/AIDS staffers Javid Syed and Claire Wingfield.
2. The Drawing Center, site of the 2007 RIAA.
3. TAG supporters Jim Gilday and Ernie Thomas at RIAA.
Tracy Swan participates in the HAART Oversight Committee meeting in London, where she advocates for better postmarketing research on anti-HIV drugs.

**JULY**


**AUGUST**

TAG publishes HCV/HIV Project Director Tracy Swan’s Guide to Hepatitis C for People Living with HIV: Testing, Coinfection, Treatment, and Support. The U.S. Food and Drug Administration (FDA) approves Pfizer’s CCR5 receptor blocker maraviroc (U.S. brand name Selzentry), the first new drug in its class.

**SEPTEMBER**

Senior Public Health Fellow at the Council on Foreign Relations Laurie Garrett—whose journalism has won the most prestigious awards in the field, the Peabody, the Polk, and the Pulitzer—holds an event in her Brooklyn Heights apartment for TAG’s Michael Palm Major Donor Circle.

Thank you, Laurie! TAG sponsors an African TB/HIV activist workshop in Kampala, Uganda. TAG’s research and policy newsletter TAGline covers a range of issues, including rapidly progressing hepatitis C in New York City gay men; the Sitges Statement on HCV Drug Development; a review of FDA hearings on HCV drug development; the changing patterns of antiretroviral treatment usage; suggestions for improving TB drug susceptibility testing; an overview of how basic research is a government responsibility; and a view of new directions in HIV research. The National Institutes of Health (NIH) stops the phase IIb study of Merck’s Adenovirus-5 (Ad5) HIV vaccine candidate due to an excess of new HIV infections among the vaccinated. Throughout the fall TAG’s Richard Jefferys provides vital coverage of the emerging story.

**OCTOBER**

Sue Perez, MPH, joins TAG as our first Federal Policy Director, establishing TAG’s presence in Washington, DC. Sue’s previous experience includes work in Côte d’Ivoire in the Peace Corps and work on tuberculosis advocacy at the RESULTS Educational Fund in Washington, DC. The FDA approves Merck’s HIV integrase inhibitor raltegravir (brand name Isentress), the first in its class. TAG’s Tracy Swan serves as ad-hoc community representative to the FDA Antiviral Drugs Advisory Committee, which recommends approval for the drug.

**NOVEMBER**


**DECEMBER**

TAG’s Mark Harrington and Richard Jefferys attend the Third International Workshop on HIV Persistence and Latency and plan a 2008 workshop to focus efforts on an HIV cure. TAG’s 2007 Research in Action Awards event honors New York City Council Speaker Christine Quinn, Harvard physician-activist and researcher Dr. Jim Yong Kim—previously the director of the World Health Organization’s HIV Department during the “3x5” initiative—and AIDS and gay/lesbian rights activist David Mixner.

7. RIAA honorees Christine Quinn and Dr. Jim Yong Kim with TAG executive director Mark Harrington and board president Barbara Hughes.
The Antiretroviral Project
The Treatment Action Group’s Antiretroviral Project closely monitors and influences the state of research on anti-HIV drug discovery, development, dissemination, and postmarketing surveillance; advocates for accelerated, better-focused efforts in this area; and focuses on innovative treatments for drug-resistant HIV that are easier to take, less toxic, and/or represent a major therapeutic breakthrough. TAG advocates for better postmarketing research on approved antiretroviral drugs to improve standards of care; works on domestic and international treatment guidelines; and educates and mobilizes policymakers, researchers, and the HIV community on anti-HIV treatment research. TAG works with academic researchers, clinicians, federal agencies such as the Food and Drug Administration (FDA) and the National Institutes of Health (NIH), and with domestic and international community coalitions to achieve these ends.

The Michael Palm HIV Pathogenesis and Prevention Project
The Treatment Action Group’s Palm Project works to improve the state of basic research on HIV/AIDS, including pathogenesis, immunology, vaccine, microbicide, and preclinical discovery and development. The Project advocates for better and faster research into the pathogenesis of HIV infection and the interactions between HIV and the immune system, for research on immune-based therapeutic approaches to HIV infection, for accelerated, scientifically rigorous HIV vaccine and microbicide research, and on projects to educate and mobilize policymakers, researchers, and the HIV community on basic science and vaccine development.

The Hepatitis/HIV Project
The Treatment Action Group’s Hepatitis/HIV Project works to improve the state of research on the opportunistic complications, infections, cancers, and coinfections related to HIV/AIDS and coinfections with viral hepatitis diseases such as hepatitis B and C. TAG advocates for greater efforts in this area while working to educate and mobilize policymakers, researchers, and the HIV community. In 2007, TAG’s efforts focused on hepatitis C virus (HCV) infection, which coinfects up to a quarter of all people with HIV in the United States and often leads to end-stage liver disease. TAG works to improve research, treatment, and community awareness of these coinfections.

The TB/HIV Advocacy Project
TAG’s TB/HIV Advocacy Project educates and empowers communities affected by HIV/AIDS domestically and internationally to understand, mobilize, and respond effectively to the challenges posed by the intersecting epidemics of tuberculosis (TB) and HIV. Worldwide, TB is the leading opportunistic infection and a leading cause of death among people living with HIV. To educate, mobilize, and empower HIV communities, TAG works to increase community understanding of TB/HIV coinfection and to increase the quality and quantity of research, treatment, and resources to combat the two epidemics.

U.S. and Global Community Education and Mobilization
TAG educates communities around the U.S. and throughout the world affected by HIV about the latest developments in research, prevention, and treatment. TAG also trains and mentors leaders of HIV/AIDS organizations and networks to strengthen their advocacy and scientific literacy. TAG staff work with individuals and organizations in the U.S. and around the world to catalyze more effective global interventions against the HIV pandemic and to strengthen treatment education and literacy efforts in developing countries.

TAG Limited Edition 2007
CAROL YAMAOKA
Roberta Smith of the New York Times has called artist Carrie Yamaoka’s work “a rejuvenation of minimalism, spurred by new materials, more refined techniques and fresh ideas.”

Carrie generously donated a limited edition of 20 works, each unique, which were offered via sponsorships of $3,500 and above for TAG’s 2007 Research in Action Awards. A limited number are still available. You can view images and purchase the work on TAG’s website, www.treatmentactiongroup.org.

Carrie is a New York-based artist and a dedicated supporter of TAG who works in a zone between painting and sculpture. She has exhibited widely in the U.S. and internationally, including at Artists Space, the Wexner Center, Mass MOCA, and the Albright-Knox Gallery.
CONTRIBUTORS 2007

$100,000 OR MORE
The Bill & Melinda Gates Foundation
The Michael Palm Foundation

$50,000—$99,000
John M. Lloyd Foundation
Merck & Co.
Newman’s Own Foundation
Schering-Plough Corporation

$50,000—$49,999
Boehringer Ingelheim Pharmaceuticals, Inc.
Bristol-Myers Squibb
Gilead Sciences, Inc.
Pfizer, Inc.
Roche and Trimeris/Hoffmann-LaRoche Inc.
Tibotec Therapeutics
World Health Organization

$10,000—$24,999
Broadway Cares/Equity Fights AIDS
David Corkery
Richard A. & Barbara Knowles Debs/
The Debs Foundation
Gesso Foundation
GlaxoSmithKline
Richard M. Lynn & Joseph Evall

$5,000—$9,999
Nicholas A.R. Debs/Debs & Co.
Pfizer Foundation
The Mary Wohlford Foundation

$2,500—$4,999
Timothy & Mary C. Casey
Randall G. Drain
Marcus Edward & Ken O’Neill
Fuse
M. Lee Garrison
James M. Goldrick
Dr. Mathilde Krim/
Mathilde & Arthur B. Krim Foundation
Michael K. Longacre
Alby P. Maccaroni, Jr.
Stephen Mack & Robert Monteleone
Mark O’Donnell & James E. McGheeve
Jason I. Osher & Richard R. Schubel
Andrew David Zacks/
The Zacks Family Foundation

$1,000—$2,499
Arcus Foundation
Jeffrey Arnstein & Michael Field
Katherine C. & Thomas M. Ash, III
Michael A. Becker & Tee Scatruorchio
David Bohnett Foundation
Michael Cowing
Constance D’Aurizio
Diamond Information Center

Steven & Judith O. Gluckstern/
The Lucky Star Foundation
David Gold
Richard & Judith Harrington
Gregory H. Hoffman & Bradford Jones
David Hollander & Robert Shaw
Barbara F. Hughes & Andrea B. Dailey
Paul E. Kennedy & John Marsh
Bonnie McEwan & Kathleen P. Duncan/
Make Waves
Robert Pini & Michael Boodro
Dr. Allan & Clare Rosenfield
James Saakviten
David Saylor & Charles Kreloff
Dr. Bruce R. Schackman & Edward K. Sikov
Nina Schwalbe & Sally Girvin/
Nina Schwalbe Fund of Tides Foundation
Evan Schwartz & Robert Fitterman
Marvin Shulman
John A. Silberman, Esq. & Elliot Carlen
Monte Steinman

$250—$499
Peter L. Allen
Dr. Gregory W. Bartha
Daniel J. Bellm & Yoel H. Kahn
Michael A. Benevento & Adam B. Gottlieb
Marc J. Berman & John Yakubik
Martin Blair & Steve Barrows
Richard M. Buxbaum & Catherine B. Hartshorn
Dr. & Mrs. Charles C.J. Carpenter
Jeanie Carstensen
Paula & Mitchell Chalfin/Neshoma Network
Dr. Gene Copello & Frederick Wright/
The AIDS Institute
Denise B. Dailey
Scott Dainton
Dinowitz & Bove CPAs
Edward Dullea & Phillip B. Miller
Alan E. Farley
Carol H. & John L. Field/
Fidelity Charitable Gift Fund
William C. Gibson & Lou Cohen
Leslie Asako Gladso
Ronald J. Goldberg & Joe Chiplock
Barry Goralnick & Keith D. Gordon
Christopher Harrington & Daphne Powell
Craig Hempstead
Marc Juris
Edward J. Kennedy
Nancy & Joel Kremsdorf
F. Joseph McConnell & Erik Haagensen
Laura A. Morrison
Donna M. Pauldine
In Memory of Jeff Palladino
Leslie Fay Pomerantz
Candida L. & Daniel S. Ramelli, III
Virun Rampersad
Lousine Shamamian/Arev Productions
Jeffrey P. Sholeen
David Sigal & Brad Hoylman
Grail Walsh Sipes
In Memory of Carl Parisi
Peter R. Staley
Margie & Mort Steinberg
Paul A. Teixeira & David A. Rimple
Daniel Tietz/ACRIA
Dr. Keith S. Tobin
Matthew D. Warnecke
P. Forrest Williams
Drs. Bret I.W. Zbar & Lori Goldman Zbar
In Honor of Laurie Garrett

Special thanks to all who have so generously helped the Treatment Action Group in its efforts in 2007 to fight for better treatment, a vaccine, and a cure for AIDS.
Palm Donor Circle
Special Recognition by TAG

The Palm Donor Circle of the Treatment Action Group is TAG’s major donor program, named in honor of philanthropist and TAG supporter Michael Palm (1951–1998). Members of the Palm Donor Circle made individual donations of $1,000 or more to TAG in 2007.

Jeffrey Arnstein & Michael Field
Katherine C. & Thomas M. Ash III
Michael A. Becker & Tee Scatuorchio
Timothy & Mary C. Casey
David Corkery
Michael Cowing
Constance D’Aurizio
Richard A. & Barbara Knowles Debs
Nicholas A. R. Debs
Randall G. Drain
Marcus Edward & Ken O’Neill
Joy Episalla & Carrie Yamaoka
M. Lee Garrison
Steven & Judith O. Gluckstern
David Gold
James M. Goldrick
Richard & Judith Harrington
Gregory H. Hoffman & Bradford Jones
David Hollander & Robert Shaw
Barbara F. Hughes & Andrea B. Dailey
Paul E. Kennedy & John Marsh

Dr. Mathilde Krim
Michael K. Longacre
Richard M. Lynn & Joseph Evall
Alby P. Maccarone, Jr.
Stephen Mack & Robert Monteleone
Bonnie McEwan & Kathleen P. Duncan
Mark O’Donnell & James E. McGreevey
Jason I. Osher & Richard R. Schubel
Robert Pini & Michael Boodro
Dr. Allan & Clare Rosenfield
James Saakvitne
David Saylor & Charles Kreloff
Dr. Bruce R. Schackman &
Edward K. Sikov
Nina Schwalbe & Sally Girvin
Evan Schwartz & Robert Fitterman
Marvin Shulman
John A. Silberman, Esq., & Elliot Carlen
Monte Steinman
W. Kirk Wallace & Mark M. Sexton
Andrew David Zacks

TAG BE INVOLVED

About TAG
Treatment Action Group is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end AIDS.

Program areas include antiretroviral treatments, basic science, vaccines, prevention, hepatitis, and tuberculosis.

Join TAG’s Board
TAG is always seeking new board members. If you are looking for a great place to invest your time and talents, please call Barbara Hughes, TAG board president, to learn more about board opportunities with TAG.

212 253 7922
barbara.hughes@treatmentactiongroup.org

Contribute!
TAG welcomes donations from individuals who want to see the AIDS research agenda remain responsive to the needs of all people living with HIV.

To make a charitable donation to TAG, call 212 253 7922 or go online to www.treatmentactiongroup.org.
TAG FINANCIALS 2007

STATEMENTS OF FINANCIAL POSITION

Assets

Current assets:
Cash and cash equivalents $ 651,189 $ 378,806
Contributions receivable 1,986,400 1,406,171
Prepaid expenses and other receivables 99,606 1,895
TOTAL CURRENT ASSETS 2,737,195 1,786,872
Property and equipment—net of accumulated depreciation 43,739 7,356
Security deposits 20,654 4,455
TOTAL ASSETS $ 2,801,588 $ 1,798,683

Liabilities and Net Assets

Current liabilities
Accounts payable and accrued expenses $ 7,054 $ 4,441
TOTAL LIABILITIES 7,054 4,441

Net assets
Unrestricted 718,134 367,238
Temporarily restricted 2,076,400 1,427,004
TOTAL NET ASSETS 2,794,534 1,794,242
TOTAL LIABILITIES AND NET ASSETS $ 2,801,588 $ 1,798,683

Statement of Cash Flows

Cash flows from operating activities:
Increase (Decrease) in net assets $ 1,000,292 $ 1,090,940
Adjustments to reconcile increase in net assets to net cash provided by operating activities:
Depreciation 6,387 4,301
(Increase) Decrease in current assets:
Contributions receivable (580,229) (1,335,546)
Prepaid expenses and other receivables (97,711) 964
Security deposits (16,198) –
(Decrease) Increase in current liabilities:
Accounts payable and accrued expenses 2,613 (911)
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES $ 315,154 $ (240,252)

Cash flows from investing activities:
Purchases of property and equipment (42,771) (3,051)
Net cash used in investing activities (42,771) (3,051)
Net decrease (increase) in cash balance 272,383 (243,303)
CASH, BEGINNING OF YEAR 378,806 622,109
CASH, END OF YEAR $ 651,189 $ 378,806
## TAG FINANCIALS 2007

### STATEMENTS OF ACTIVITIES

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Year ended December 31</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue and support:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct mail</td>
<td>$ 36,108</td>
<td>$ –</td>
<td>$ 36,108</td>
</tr>
<tr>
<td>Donations</td>
<td>31,754</td>
<td>33,130</td>
<td>64,884</td>
</tr>
<tr>
<td>Grants</td>
<td>446,100</td>
<td>1,964,270</td>
<td>2,410,370</td>
</tr>
<tr>
<td>Special event income</td>
<td>147,782</td>
<td>–</td>
<td>147,782</td>
</tr>
<tr>
<td>Travel and other reimbursement</td>
<td>18,828</td>
<td>18,750</td>
<td>37,578</td>
</tr>
<tr>
<td>Interest and dividend income</td>
<td>9,237</td>
<td>43,131</td>
<td>52,368</td>
</tr>
<tr>
<td><strong>Net assets released from restrictions</strong></td>
<td>1,409,885</td>
<td>(1,409,885)</td>
<td>–</td>
</tr>
<tr>
<td><strong>TOTAL REVENUE AND SUPPORT</strong></td>
<td>2,099,694</td>
<td>649,396</td>
<td>2,749,090</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2,199,935</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program Services</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiretroviral Project</td>
<td>68,067</td>
<td>–</td>
<td>68,087</td>
</tr>
<tr>
<td>Federal Policy Project</td>
<td>61,325</td>
<td>–</td>
<td>61,325</td>
</tr>
<tr>
<td>Michael Palm HIV Pathogenesis &amp; Prevention Project</td>
<td>182,491</td>
<td>–</td>
<td>182,491</td>
</tr>
<tr>
<td>Hepatitis/HIV Project</td>
<td>163,800</td>
<td>–</td>
<td>163,800</td>
</tr>
<tr>
<td>TB/HIV Advocacy Project</td>
<td>1,026,610</td>
<td>–</td>
<td>1,026,610</td>
</tr>
<tr>
<td>U.S. &amp; Global Community Education &amp; Mobilization</td>
<td>7,819</td>
<td>–</td>
<td>7,819</td>
</tr>
<tr>
<td>TAG Publications and Website</td>
<td>92,373</td>
<td>–</td>
<td>92,373</td>
</tr>
<tr>
<td><strong>TOTAL PROGRAM EXPENSES</strong></td>
<td>1,602,485</td>
<td>–</td>
<td>1,602,485</td>
</tr>
<tr>
<td><strong>Management and general</strong></td>
<td>84,659</td>
<td>–</td>
<td>84,659</td>
</tr>
<tr>
<td><strong>Fundraising</strong></td>
<td>61,654</td>
<td>–</td>
<td>61,654</td>
</tr>
<tr>
<td><strong>TOTAL SERVICES EXPENSES</strong></td>
<td>1,748,798</td>
<td>–</td>
<td>1,748,798</td>
</tr>
<tr>
<td><strong>Increase in net assets</strong></td>
<td>350,896</td>
<td>649,396</td>
<td>1,000,292</td>
</tr>
<tr>
<td><strong>Net assets, beginning of year</strong></td>
<td>367,238</td>
<td>1,427,004</td>
<td>1,794,242</td>
</tr>
<tr>
<td><strong>NET ASSETS, END OF YEAR</strong></td>
<td>718,134</td>
<td>2,076,400</td>
<td>2,794,534</td>
</tr>
</tbody>
</table>
